Last updated: May 29, 2026
DEXTENZA (dexamethasone ophthalmic insert) is supplied in the US as a sterile, sustained-release intracanalicular implant. The supplier and manufacturing chain is anchored by the branded product’s label holder and the company manufacturing the insert and packaging for commercial distribution.
Who manufactures DEXTENZA (dexamethasone) inserts?
Direct answer: DEXTENZA is manufactured and supplied through the product’s branded supply chain under the label holder responsible for FDA marketing authorization and commercial supply. The insert is produced as a sterile ophthalmic sustained-release device.
What companies are listed as manufacturer or labeler on FDA submissions and labeling?
The DEXTENZA product listing and prescribing information identify a US marketing authorization holder and include manufacturing/packaging responsibilities for the commercial supply chain.
What is the role of third-party manufacturers in ophthalmic inserts?
Intracanalicular inserts typically involve a dedicated device/sterile manufacturing operation plus packaging, labeling, and distribution workflows governed by cGMP and sterile product controls. For branded ophthalmic sustained-release implants, the key supplier question is whether the same entity performs:
- sterile manufacture of the insert matrix/drug load,
- sterile filling/containment into the applicator/delivery system,
- final packaging and distribution release.
What is the US FDA regulatory status of DEXTENZA for supply chain decisions?
Direct answer: DEXTENZA is an FDA-approved prescription ophthalmic insert with a specific marketing authorization and labeling profile that governs which manufacturers can legally produce and distribute the product in the US.
What FDA pathway affects suppliers?
Because DEXTENZA is already approved, supplier eligibility for commercial supply depends on:
- listing in FDA product databases for the marketed drug,
- cGMP manufacturing capacity for the final dosage form,
- sterile manufacturing and packaging controls for an ophthalmic implant.
What is the Orange Book status of DEXTENZA and how does that affect sourcing?
Direct answer: The Orange Book listing determines whether generic or “same drug, same dosage form” products can source the active ingredient with substitutable approval pathways. If Orange Book shows only a limited patent or exclusivity footprint, it can reduce branded-supplier dependency over time. If it shows active exclusivity or patents, branded sourcing remains commercially dominant.
Are there listed generics or authorized generics for DEXTENZA?
Orange Book status determines whether other manufacturers are approved for substitution. If no approved generic is listed, branded supply is typically the only source.
What patents protect DEXTENZA supply and restrict generic manufacture?
Direct answer: DEXTENZA’s patent estate can restrict entry of generics and biosimilar-style “follow-on” supply by delaying FDA approval for non-bridge indications, certain formulations, or manufacturing methods covered by patent claims.
Which patent types matter for supplier selection?
For an ophthalmic sustained-release insert, supplier risk is tied to patents in:
- formulation and drug loading,
- the delivery system or applicator interface,
- manufacturing method claims for producing the implant,
- method-of-use claims (where applicable).
What generic entry risks exist for DEXTENZA suppliers?
Direct answer: Generic entry risk is driven by:
- patent and exclusivity expiration,
- whether Paragraph IV challenges are filed,
- whether a generic can demonstrate sameness without infringing protected formulation or manufacturing methods.
What drives supply chain disruption once patents expire?
Once exclusivity/patents expire, additional approved suppliers can appear if they can validate:
- bioavailability/clinical performance comparability where required,
- sterile quality systems for ophthalmic implants,
- consistency of dexamethasone release profile.
Which suppliers can build the DEXTENZA value chain (active, device, packaging)?
Direct answer: In ophthalmic sustained-release inserts, the value chain typically separates into:
- upstream API sourcing for dexamethasone,
- drug-in-device manufacturing (sterile implant),
- packaging and distribution (sterile barrier, labeling, applicator system).
How do API suppliers differ from insert manufacturers?
Even when multiple API suppliers exist for dexamethasone, the insert manufacturing step is the bottleneck for commercial supply because it must meet sterile, release-profile, and stability specifications under the approved product’s manufacturing controls.
What are the bottleneck steps in implant supply?
Key constraints usually include:
- sterile manufacture of the implant matrix,
- drug loading and uniformity controls,
- final sterilization strategy compatible with sustained release performance,
- stability shelf-life and distribution qualification for the ophthalmic device.
How does DEXTENZA compare with other ophthalmic steroid implants on supplier structure?
Direct answer: DEXTENZA competes on sustained-release steroid delivery, but supplier structures differ by implant type (intracanalicular vs intravitreal) and the complexity of sterile delivery and device components.
Key differentiators that affect suppliers
- implant placement and device complexity (intracanalicular vs intravitreal),
- regulatory classification of the drug-device combination,
- sterility assurance and stability requirements.
Key Takeaways
- DEXTENZA supply in the US is controlled by the branded marketing authorization holder and the cGMP manufacturers that produce and package the sterile dexamethasone intracanalicular insert.
- Supplier concentration risk is highest at the sterile drug-in-device manufacturing and packaging stages, not at dexamethasone API supply.
- Generic or follow-on supply depends on Orange Book status, exclusivity, and the patent estate covering formulation and insert manufacturing methods.
- Patent and exclusivity timelines determine when additional approved manufacturers can enter and reduce dependence on the branded supplier chain.
FAQs
1) What company is the US labeler for DEXTENZA?
The labeler is the FDA marketing authorization holder shown on DEXTENZA prescribing information and FDA product databases.
2) Is there more than one manufacturer for DEXTENZA inserts and packaging?
The existence of multiple manufacturing sites depends on FDA-approved manufacturing and packaging listings tied to the marketed product.
3) Can a generic supplier use the same dexamethasone API but different implant manufacturing?
A generic must meet FDA sameness expectations for the dosage form and avoid infringement of formulation and manufacturing method patents.
4) Do sterile manufacturing and sterilization methods constrain DEXTENZA supplier entry?
Yes. The insert must be produced and packaged under cGMP sterile product controls consistent with the approved drug-device product.
5) Does Orange Book listing drive when new DEXTENZA suppliers enter?
Orange Book listings plus exclusivity and patent status determine when FDA-approved non-branded products can launch.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Orange Book database).
- FDA. Drugs@FDA: DEXTENZA (dexamethasone ophthalmic insert) product page and labeling. (Drugs@FDA database).
- DEXTENZA. Prescribing information. (US label).
